| First Author | Garg R | Year | 2017 |
| Journal | Cell Rep | Volume | 19 |
| Issue | 2 | Pages | 375-388 |
| PubMed ID | 28402859 | Mgi Jnum | J:254381 |
| Mgi Id | MGI:6103174 | Doi | 10.1016/j.celrep.2017.03.042 |
| Citation | Garg R, et al. (2017) Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway. Cell Rep 19(2):375-388 |
| abstractText | PKCepsilon, an oncogenic member of the PKC family, is aberrantly overexpressed in epithelial cancers. To date, little is known about functional interactions of PKCepsilon with other genetic alterations, as well as the effectors contributing to its tumorigenic and metastatic phenotype. Here, we demonstrate that PKCepsilon cooperates with the loss of the tumor suppressor Pten for the development of prostate cancer in a mouse model. Mechanistic analysis revealed that PKCepsilon overexpression and Pten loss individually and synergistically upregulate the production of the chemokine CXCL13, which involves the transcriptional activation of the CXCL13 gene via the non-canonical nuclear factor kappaB (NF-kappaB) pathway. Notably, targeted disruption of CXCL13 or its receptor, CXCR5, in prostate cancer cells impaired their migratory and tumorigenic properties. In addition to providing evidence for an autonomous vicious cycle driven by PKCepsilon, our studies identified a compelling rationale for targeting the CXCL13-CXCR5 axis for prostate cancer treatment. |
